A phase I trial of intracranial dendritic cell immunotherapy for patients with malignant glioma

被引：0
|
作者：
Yu, John S.
Liu, Gentao
Ng, Hiushan
Wagenberg, Mia
Luptrawan, Anne
Mindlin, Elina
Wheeler, Christopher J.
Black, Keith L.
机构：
来源：
NEUROSURGERY | 2006年 / 59卷 / 02期
关键词：
D O I：
10.1227/00006123-200608000-00132
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [41] A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma
    Desjardins, A.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Sathornsumetee, S.
    Gururangan, S.
    Friedman, A. H.
    Berg, W.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    Reardon, D. A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 441 - 441
  • [42] Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy
    Walker, David G.
    Laherty, Richard
    Tomlinson, Frank H.
    Chuah, Teong
    Schmidt, Chris
    JOURNAL OF CLINICAL NEUROSCIENCE, 2008, 15 (02) : 114 - 121
  • [43] Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma
    Sathornsumetee, Sith
    Rich, Jeremy N.
    Vredenburgh, James J.
    Desjardins, Annick
    Quinn, Jennifer A.
    Gururangan, Sri
    Friedman, Allan H.
    Egorin, Merrill J.
    Salvado, August
    Friedman, Henry S.
    Reardon, David A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 451 - 451
  • [44] Phase I trial of O6-benzylguanine plus BCNU for patients with recurrent malignant glioma
    Quinn, JA
    Friedman, AH
    Pluda, J
    Bigner, DD
    Pegg, AE
    NEUROLOGY, 2000, 54 (07) : A32 - A33
  • [45] A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.
    Reardon, D.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Sathornsumetee, S.
    Gururangan, S.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 77S - 77S
  • [46] Immunological evaluation of personalized peptide vaccination for patients with malignant glioma: the results of a clinical phase I trial
    Yamanaka, Ryuya
    Yajima, Naoki
    Sano, Masakazu
    Homma, Junpei
    Tanaka, Ryuichi
    Kuramoto, Terukazu
    Shigemori, Minoru
    Obata, Yayoi
    Yamada, Akira
    Mine, Takashi
    Ito, Kyogo
    CANCER RESEARCH, 2006, 66 (08)
  • [47] Dendritic cell-based glioma immunotherapy (Review)
    Yamanaka, R
    Yajima, N
    Abe, T
    Tsuchiya, N
    Homma, J
    Narita, M
    Takahashi, M
    Tanaka, R
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 23 (01) : 5 - 15
  • [48] AUTOLOGOUS DENDRITIC CELL-BASED IMMUNOTHERAPY FOR MALIGNANT GLIOMAS-A PHASE II PROSPECTIVE RANDOMIZED CLINICAL TRIAL
    Cho, Der-Yang
    Lee, Han-Chung
    Lin, Hon-Lin
    NEURO-ONCOLOGY, 2009, 11 (06) : 882 - 882
  • [49] Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
    Reardon, DA
    Quinn, JA
    Rich, JN
    Desjardins, A
    Vredenburgh, J
    Gururangan, S
    Sathornsumetee, S
    Badruddoja, M
    McLendon, R
    Provenzale, J
    Herndon, JE
    Dowell, JM
    Burkart, JL
    Newton, HB
    Friedman, AH
    Friedman, HS
    CANCER, 2005, 104 (07) : 1478 - 1486
  • [50] In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma
    Maes, W.
    Deroose, C.
    Reumers, V.
    Krylyshkina, O.
    Gijsbers, R.
    Baekelandt, V.
    Ceuppens, J.
    Debyser, Z.
    Van Gool, S. W.
    JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (02) : 127 - 139
12345